Clinical Potential of Matrix Metalloprotease Inhibitors in Cancer Therapy

摘要: Matrix metalloproteases (MMP) are a family of enzymes that contribute to the degradation extracellular matrix. The destruction matrix eventually leads tumour invasion, metastasis and angiogenesis. Realising this mechanism action, there is tremendous potential for inhibitors MMP in cancer therapy. Extensive preclinical data have shown administration metalloprotease (MMPI) different animal models results reduction primary growth as well number size metastatic lesions. Based on promising studies, synthetic MMPI been developed taken into clinical trials. These include marimastat, BAY-129566, CGS-27023A, prinomastat (AG-3340), BMS-275291 metastat (COL-3). drugs all stages development, ranging from phase I III. In general, musculoskeletal problems, such joint stiffness pain hands, arms shoulders seem affect most patients varying degrees, depending dose type compound administered. addition single agent therapy, several entered trials combination objective combining chemotherapy with an potentiate cytotoxicity reduce Several compounds III therapy trials, but it still too early report any data. There ongoing research correlating biological end-points, levels markers angiogenesis response. As field their continues mature, its role therapeutics will be better defined.